Proteomic and genomic studies of non-alcoholic fatty liver disease - Clues in the pathogenesis

World Journal of Gastroenterology

Volumn , Issue 26, 2014, Pages 8325-8340

  Lim, Jun Wei ^a   Dillon, John ^a   Miller, Michael ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Genomics; Metabolic syndrome; Non alcoholic fatty liver disease; Pathophysiology; Proteomics

Indexed keywords

ADIPOCYTOKINE RECEPTOR; BILIRUBIN; C REACTIVE PROTEIN; CARBAMOYL PHOSPHATE SYNTHASE; CARRIER PROTEIN; GELATINASE B; GLUCOSE REGULATED PROTEIN 78; INTERLEUKIN 6; LEPTIN RECEPTOR; MATRIX METALLOPROTEINASE; PENTRAXIN 3; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; GENETIC MARKER; PROTEIN; ACUTE PHASE PROTEIN; ADIPOCYTOKINE; HEME OXYGENASE 1;

CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; FIBROGENESIS; GENETIC POLYMORPHISM; GENOMICS; HUMAN; HYPERLIPIDEMIA; IMMUNOCOMPETENT CELL; INSULIN RESISTANCE; LIPOLYSIS; LIVER INJURY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; ACUTE PHASE RESPONSE; BILIRUBIN BLOOD LEVEL; FATTY LIVER; IMMUNE SYSTEM; INFLAMMATION; LIVER DISEASE; LIVER FIBROGENESIS; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TRANSPORT; RISK FACTOR;

ANIMALS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; GENETIC MARKERS; GENOMICS; HUMANS; INFLAMMATION MEDIATORS; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEINS; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 84904395679     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i26.8325     Document Type: Review

References (146)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x]
2. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13: 3540-3553 [PMID: 17659704] (Pubitemid 47162261)
3. Bellentani S, Bedogni G, Tiribelli C. Liver and heart: a new link? J Hepatol 2008; 49: 300-302 [PMID: 18554746 DOI: 10.1016/j.jhep.2008.05.003]
4. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006; 91: 4753-4761 [PMID: 16968800 DOI: 10.1210/jc.2006-0587] (Pubitemid 44917301)
5. Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res 2007; 149: 114-125 [PMID: 17320797 DOI: 10.1016/j.trsl.2006.11.011] (Pubitemid 46275574)
6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10.1002/hep.25762]
7. Bedossa P . Current histological classification of NAFLD: strength and limitations. Hepatol Int 2013; 7: 765-770 [DOI: 10.1007/s12072-013-9446-z]
8. Pandey A, Mann M. Proteomics to study genes and genomes. Nature 2000; 405: 837-846 [PMID: 10866210 DOI: 10.1038/35015709] (Pubitemid 30407862)
9. Manolio TA, Collins FS. The HapMap and genome-wide association studies in diagnosis and therapy. Annu Rev Med 2009; 60: 443-456 [PMID: 19630580 DOI: 10.1146/annurev.med.60.061907.093117]
10. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102]
11. Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-823 [PMID: 22966992 DOI: 10.1111/apt.12046]
12. Hernaez R. Genetics of non-alcoholic fatty liver disease and associated metabolic disorders. Avances en Diabetología 2011; 27: 186-97 [DOI: 10.1016/j.avdiab.2011.11.004]
13. Asrih M, Jornayvaz FR. Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance. J Endocrinol 2013; 218: R25-R36 [PMID: 23833274 DOI: 10.1530/joe-13-0201]
14. Lucchesi AN, Freitas NT, Cassettari LL, Marques SF, Spadella CT. Diabetes mellitus triggers oxidative stress in the liver of alloxan-treated rats: a mechanism for diabetic chronic liver disease. Acta Cir Bras 2013; 28: 502-508 [PMID: 23842931]
15. Friedman SL . Mac the knife? Macrophages- the double-edged sword of hepatic fibrosis. J Clin Invest 2005; 115: 29-32 [PMID: 15630440 DOI: 10.1172/jci23928] (Pubitemid 40385501)
16. Mas VR, Fisher RA, Archer KJ, Maluf DG. Proteomics and liver fibrosis: identifying markers of fibrogenesis. Expert Rev Proteomics 2009; 6: 421-431 [PMID: 19681677 DOI: 10.1586/epr.09.59]
17. Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42: 665-674 [PMID: 16116632 DOI: 10.1002/hep.20838] (Pubitemid 41233660)
18. Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010; 51: 111-120 [PMID: 19885878 DOI: 10.1002/hep.23271]
19. Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013; 33: 1398-1405 [PMID: 23763360 DOI: 10.1111/liv.12226]
20. Li YY . Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18: 6546-6551 [PMID: 23236228 DOI: 10.3748/wjg.v18.i45.6546]
21. Choe YG, Jin W, Cho YK, Chung WG, Kim HJ, Jeon WK, Kim BI. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. J Gastroenterol Hepatol 2013; 28: 678-683 [PMID: 23215811 DOI: 10.1111/jgh.12077]
22. Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM, Reeves HL. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer 2009; 9: 271 [PMID: 19656391 DOI: 10.1186/1471-2407-9-271]
23. Sarrias MR, Roselló S, Sánchez-Barbero F, Sierra JM, Vila J, Yélamos J, Vives J, Casals C, Lozano F. A role for human Sp alpha as a pattern recognition receptor. J Biol Chem 2005; 280: 35391-35398 [PMID: 16030018 DOI: 10.1074/jbc.M505042200] (Pubitemid 41532728)
24. Rodríguez-Suárez E, Duce AM, Caballería J, Martínez Arrieta F, Fernández E, Gómara C, Alkorta N, Ariz U, Martínez-Chantar ML, Lu SC, Elortza F, Mato JM. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl 2010; 4: 362-371 [PMID: 21137056 DOI: 10.1002/prca.200900119]
25. Luo S, Mao C, Lee B, Lee AS. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol Cell Biol 2006; 26: 5688-5697 [PMID: 16847323 DOI: 10.1128/mcb.00779-06] (Pubitemid 44134326)
26. Lee AS . The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 2005; 35: 373-381 [PMID: 15804610 DOI: 10.1016/j.ymeth.2004.10.010] (Pubitemid 40445371)
27. Kammoun HL, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T, Ferré P, Foufelle F. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest 2009; 119: 1201-1215 [PMID: 19363290 DOI: 10.1172/jci37007]
28. Rector RS, Thyfault JP, Uptergrove GM, Morris EM, Naples SP, Borengasser SJ, Mikus CR, Laye MJ, Laughlin MH, Booth FW, Ibdah JA. Mitochondrial dysfunction precedes insulin resistance and hepatic steatosis and contributes to the natural history of non-alcoholic fatty liver disease in an obese rodent model. J Hepatol 2010; 52: 727-736 [PMID: 20347174 DOI: 10.1016/j.jhep.2009.11.030]
29. Ibdah JA . "Oxidative stress-mediated mitochondrial dysfunction contributes to angiotension II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats". Note of concern. Am J Pathol 2009; 175: 2709-2710 [PMID: 19965804 DOI: 10.2353/ajpath.2009.090921]
30. Wei Y, Clark SE, Thyfault JP, Uptergrove GM, Li W, Whaley-Connell AT, Ferrario CM, Sowers JR, Ibdah JA. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol 2009; 174: 1329-1337 [PMID: 19246643 DOI: 10.2353/ajpath.2009.080697]
31. Nakagawa T, Lomb DJ, Haigis MC, Guarente L. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009; 137: 560-570 [PMID: 19410549 DOI: 10.1016/j.cell.2009.02.026]
32. Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS One 2010; 5: e11578 [PMID: 20644649 DOI: 10.1371/journal.pone.0011578]
33. Sirota JC, McFann K, Targher G, Johnson RJ, Chonchol M, Jalal DI. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 2013; 62: 392-399 [PMID: 23036645 DOI: 10.1016/j.metabol.2012.08.013]
34. Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, Gao P, Tian XJ, Liu JS, Zhu ZH, Huang K, Zhang C. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PLoS One 2013; 8: e56864 [PMID: 23437258 DOI: 10.1371/journal.pone.0056864]
35. Berezin AE, Kremzer AA. Serum uric Acid as a marker of coronary calcification in patients with asymptomatic coronary artery disease with preserved left ventricular pump function. Cardiol Res Pract 2013; 2013: 129369 [PMID: 23607043 DOI: 10.1155/2013/129369]
36. Petta S, Macaluso FS, Cammà C, Marco VD, Cabibi D, Craxì A. Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. Liver Int 2012; 32: 1443-1450 [PMID: 22764879 DOI: 10.1111/j.1478-3231.2012.02842.x]
37. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, Ishimoto T, Sautin YY, Lanaspa MA. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013; 62: 3307-3315 [PMID: 24065788 DOI: 10.2337/db12-1814]
38. Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313-326 [PMID: 21040935 DOI: 10.1016/j.metabol.2010.09.003]
39. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 573-582 [PMID: 17653654 DOI: 10.1007/s00535-007-2060-x] (Pubitemid 47190075)
40. Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, Iannelli A, Gugenheim J, Bedossa P, Francque S, Le Marchand-Brustel Y, Clement K, Van Gaal L, Sørensen TI, Jess T. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol 2011; 55: 660-665 [PMID: 21238518 DOI: 10.1016/j.jhep.2010.12.017]
41. Trak-Smayra V, Dargere D, Noun R, Albuquerque M, Yaghi C, Gannagé-Yared MH, Bedossa P, Paradis V. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009; 58: 825-832 [PMID: 18403495 DOI: 10.1136/gut.2007.140087]
42. Yu C, Xu C, Xu L, Yu J, Miao M, Li Y. Serum proteomic analysis revealed diagnostic value of hemoglobin for nonalcoholic fatty liver disease. J Hepatol 2012; 56: 241-247 [PMID: 21756851 DOI: 10.1016/j.jhep.2011.05.027]
43. Xu L, Xu CF, Yu CH, Miao M, Li YM. Haemoglobin and non-alcoholic fatty liver disease: further evidence from a population-based study. Gut 2009; 58: 1706-1707 [PMID: 19923352 DOI: 10.1136/gut.2009.186668]
44. Kamada Y, Akita M, Takeda Y, Yamada S, Fujii H, Sawai Y, Doi Y, Asazawa H, Nakayama K, Mizutani K, Fujii H, Yakushijin T, Miyazaki M, Ezaki H, Hiramatsu N, Yoshida Y, Kiso S, Imai Y, Kawada N, Takehara T, Miyoshi E. Serum Fucosylated Haptoglobin as a Novel Diagnostic Biomarker for Predicting Hepatocyte Ballooning and Nonalcoholic Steatohepatitis. PLoS One 2013; 8: e66328 [PMID: 23805214 DOI: 10.1371/journal.pone.0066328]
45. Nakagawa T, Moriwaki K, Terao N, Nakagawa T, Miyamoto Y, Kamada Y, Miyoshi E. Analysis of polarized secretion of fucosylated alpha-fetoprotein in HepG2 cells. J Proteome Res 2012; 11: 2798-2806 [PMID: 22483194 DOI: 10.1021/pr201154k]
46. Bastrup-Birk S, Skjoedt MO, Munthe-Fog L, Strom JJ, Ma YJ, Garred P. Pentraxin-3 serum levels are associated with disease severity and mortality in patients with systemic inflammatory response syndrome. PLoS One 2013; 8: e73119 [PMID: 24039869 DOI: 10.1371/journal.pone.0073119]
47. Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, Mawatari H, Iida H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Kobayashi N, Kubota K, Saito S, Maeyama S, Sagara M, Aburatani H, Kodama T, Nakajima A. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol 2008; 8: 53 [PMID: 19014569 DOI: 10.1186/1471-230x-8-53]
48. Karakas MF, Buyukkaya E, Kurt M, Motor S, Akcay AB, Karakas E, Buyukkaya Ş, Sen N. Serum pentraxin-3 levels are associated with the severity of metabolic syndrome. Med Princ Pract 2013; 22: 274-279 [PMID: 23146973 DOI: 10.1159/000343904]
49. Kwak MS, Kim D, Chung GE, Kang SJ, Park MJ, Kim YJ, Yoon JH, Lee HS. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. Clin Mol Hepatol 2012; 18: 383-390 [PMID: 23323254 DOI: 10.3350/cmh.2012.18.4.383]
50. Chang Y, Ryu S, Zhang Y, Son HJ, Kim JY, Cho J, Guallar E. A cohort study of serum bilirubin levels and incident nonalcoholic fatty liver disease in middle aged Korean workers. PLoS One 2012; 7: e37241 [PMID: 22615952 DOI: 10.1371/journal.pone.0037241]
51. Hjelkrem M, Morales A, Williams CD, Harrison SA. Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH). Aliment Pharmacol Ther 2012; 35: 1416-1423 [PMID: 22540836 DOI: 10.1111/j.1365-2036.2012.05114.x]
52. Mayer M . Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 2000; 46: 1723-1727 [PMID: 11067805]
53. Collino M, Pini A, Mugelli N, Mastroianni R, Bani D, Fantozzi R, Papucci L, Fazi M, Masini E. Beneficial effect of prolonged heme oxygenase 1 activation in a rat model of chronic heart failure. Dis Model Mech 2013; 6: 1012-1020 [PMID: 23592614 DOI: 10.1242/dmm.011528]
54. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 2004; 113: 1776-1782 [PMID: 15173506] (Pubitemid 38697991)
55. Li L, Grenard P, Nhieu JT, Julien B, Mallat A, Habib A, Lotersztajn S. Heme oxygenase-1 is an antifibrogenic protein in human hepatic myofibroblasts. Gastroenterology 2003; 125: 460-469 [PMID: 12891549]
56. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2006; 21: 1459-1465 [PMID: 16911693 DOI: 10.1111/j.1440-1746.2006.04447.x] (Pubitemid 44154717)
57. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005; 25: 779-786 [PMID: 15998429 DOI: 10.1111/j.1478-3231.2005.01064.x] (Pubitemid 41038659)
58. Santos VN, Leite-Mór MM, Kondo M, Martins JR, Nader H, Lanzoni VP, Parise ER. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005; 38: 747-753 [PMID: 15917956] (Pubitemid 40867514)
59. Yoneda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol 2007; 42: 375-381 [PMID: 17530362 DOI: 10.1007/s00535-007-2014-3] (Pubitemid 47097254)
60. Gabrielli GB, Capra F, Casaril M, Corrocher R, Colombari R, De Sandre G. Serum laminin P1 in chronic viral hepatitis: correlations with liver histological activity and diagnostic value. Clin Chim Acta 1996; 252: 171-180 [PMID: 8853564] (Pubitemid 26246302)
61. Peters L, Mocroft A, Soriano V, Rockstroh J, Rauch A, Karlsson A, Knysz B, Pradier C, Zilmer K, Lundgren JD. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients. PLoS One 2013; 8: e64283 [PMID: 23724041 DOI: 10.1371/journal.pone.0064283]
62. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11: 255-259 [PMID: 15633226] (Pubitemid 40125214)
63. Charlton M, Viker K, Krishnan A, Sanderson S, Veldt B, Kaalsbeek AJ, Kendrick M, Thompson G, Que F, Swain J, Sarr M. Differential expression of lumican and fatty acid binding protein-1: new insights into the histologic spectrum of nonalcoholic fatty liver disease. Hepatology 2009; 49: 1375-1384 [PMID: 19330863 DOI: 10.1002/hep.22927]
64. Krishnan A, Li X, Kao WY, Viker K, Butters K, Masuoka H, Knudsen B, Gores G, Charlton M. Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. Lab Invest 2012; 92: 1712-1725 [PMID: 23007134 DOI: 10.1038/labinvest.2012.121]
65. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 2005; 45: 657-687 [PMID: 15822192 DOI: 10.1146/annurev.pharmtox.45.120403.095802] (Pubitemid 40261821)
66. Engebretsen KV, Lunde IG, Strand ME, Waehre A, Sjaastad I, Marstein HS, Skrbic B, Dahl CP, Askevold ET, Christensen G, Bjørnstad JL, Tønnessen T. Lumican is increased in experimental and clinical heart failure, and its production by cardiac fibroblasts is induced by mechanical and proinflammatory stimuli. FEBS J 2013; 280: 2382-2398 [PMID: 23480731 DOI: 10.1111/febs.12235]
67. Wanninger J, Walter R, Bauer S, Eisinger K, Schäffler A, Dorn C, Weiss TS, Hellerbrand C, Buechler C. MMP-9 activity is increased by adiponectin in primary human hepatocytes but even negatively correlates with serum adiponectin in a rodent model of non-alcoholic steatohepatitis. Exp Mol Pathol 2011; 91: 603-607 [PMID: 21791204 DOI: 10.1016/j.yexmp.2011.07.001]
68. Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 2008; 19: 34-41 [PMID: 17707664 DOI: 10.1016/j.semcdb.2007.07.003] (Pubitemid 350235986)
69. Arthur MJ . Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2000; 279: G245-G249 [PMID: 10915630]
70. Mahmoud AA, Bakir AS, Shabana SS. Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. Saudi J Gastroenterol 2012; 18: 327-333 [PMID: 23006461 DOI: 10.4103/1319-3767.101132]
71. Lichtinghagen R, Bahr MJ, Wehmeier M, Michels D, Haberkorn CI, Arndt B, Flemming P, Manns MP, Boeker KH. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond) 2003; 105: 373-382 [PMID: 12760742 DOI: 10.1042/cs20030098] (Pubitemid 37088577)
72. D'Amico F, Consolo M, Amoroso A, Skarmoutsou E, Mauceri B, Stivala F, Malaponte G, Bertino G, Neri S, Mazzarino MC. Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection. Acta Histochem 2010; 112: 474-481 [PMID: 19604544 DOI: 10.1016/j.acthis.2009.05.005]
73. de Meijer VE, Sverdlov DY, Le HD, Popov Y, Puder M. Tissue-specific differences in inflammatory infiltrate and matrix metalloproteinase expression in adipose tissue and liver of mice with diet-induced obesity. Hepatol Res 2012; 42: 601-610 [PMID: 22236199 DOI: 10.1111/j.1872-034X.2011.00960.x]
74. Zhan YT, An W. Roles of liver innate immune cells in nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 4652-4660 [PMID: 20872965]
75. Maina V, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, Albano E. Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond) 2012; 122: 545-553 [PMID: 22142284 DOI: 10.1042/cs20110366]
76. Inzaugarat ME, Ferreyra Solari NE, Billordo LA, Abecasis R, Gadano AC, Cherñavsky AC. Altered phenotype and functionality of circulating immune cells characterize adult patients with nonalcoholic steatohepatitis. J Clin Immunol 2011; 31: 1120-1130 [PMID: 21845516 DOI: 10.1007/s10875-011-9571-1]
77. Ferreyra Solari NE, Inzaugarat ME, Baz P, De Matteo E, Lezama C, Galoppo M, Galoppo C, Cherñavsky AC. The role of innate cells is coupled to a Th1-polarized immune response in pediatric nonalcoholic steatohepatitis. J Clin Immunol 2012; 32: 611-621 [PMID: 22228550 DOI: 10.1007/s10875-011-9635-2]
78. Martel C, Esposti DD, Bouchet A, Brenner C, Lemoine A. Non-alcoholic steatohepatitis: new insights from OMICS studies. Curr Pharm Biotechnol 2012; 13: 726-735 [PMID: 22122481]
79. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18: 727-735 [PMID: 22371632 DOI: 10.3748/wjg.v18.i8.727]
80. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleu-kin- 6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008; 103: 1372-1379 [PMID: 18510618 DOI: 10.1111/j.1572-0241.2007.01774.x] (Pubitemid 351813900)
81. Haukeland JW, Dama˚s JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44: 1167-1174 [PMID: 16618517 DOI: 10.1016/j.jhep.2006.02.011]
82. Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010; 7: 682-690 [PMID: 20975742 DOI: 10.1038/nrgastro.2010.168]
83. Kirovski G, Dorn C, Huber H, Moleda L, Niessen C, Wobser H, Schacherer D, Buechler C, Wiest R, Hellerbrand C. Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation. Exp Mol Pathol 2011; 91: 780-783 [PMID: 21855538 DOI: 10.1016/j.yexmp.2011.08.001]
84. Alkhouri N, Lopez R, Berk M, Feldstein AE. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2009; 43: 985-989 [PMID: 19525859 DOI: 10.1097/MCG.0b013e3181a0998d]
85. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362 [PMID: 16034410 DOI: 10.1038/nature03711] (Pubitemid 41065039)
86. Saki F, Karamizadeh Z, Honar N, Moravej H, Ashkani-Esfahani S, Namvar Shooshtarian MH. Association of Plasma Retinol Binding Protein-4 (RBP4) and Sonographic Grading of Fatty Liver in Obese Iranian Children. Hepat Mon 2012; 12: e7103 [PMID: 23423766 DOI: 10.5812/hepatmon.7103]
87. Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563 [PMID: 16775236 DOI: 10.1056/NEJMoa054862] (Pubitemid 43882351)
88. Christou GA, Tselepis AD, Kiortsis DN. The metabolic role of retinol binding protein 4: an update. Horm Metab Res 2012; 44: 6-14 [PMID: 22205567 DOI: 10.1055/s-0031-1295491]
89. Kotnik P, Fischer-Posovszky P, Wabitsch M. RBP4: a controversial adipokine. Eur J Endocrinol 2011; 165: 703-711 [PMID: 21835764 DOI: 10.1530/eje-11-0431]
90. Esteve E, Ricart W, Fernández-Real JM. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care 2009; 32 Suppl 2: S362-S367 [PMID: 19875582 DOI: 10.2337/dc09-S340]
91. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]
92. Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 2012; 7: e38322 [PMID: 22719876 DOI: 10.1371/journal.pone.0038322]
93. Peng XE, Wu YL, Lin SW, Lu QQ, Hu ZJ, Lin X. Genetic variants in PNPLA3 and risk of non-alcoholic fatty liver disease in a Han Chinese population. PLoS One 2012; 7: e50256 [PMID: 23226254 DOI: 10.1371/journal.pone.0050256]
94. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894 [PMID: 21381068 DOI: 10.1002/hep.24283]
95. Dubuquoy C, Burnol AF, Moldes M. PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function? Clin Res Hepatol Gastroenterol 2013; 37: 30-35 [PMID: 22884299 DOI: 10.1016/j.clinre.2012.06.014]
96. Wang CW, Lin HY, Shin SJ, Yu ML, Lin ZY, Dai CY, Huang JF, Chen SC, Li SS, Chuang WL. The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population. Liver Int 2011; 31: 1326-1331 [PMID: 21745282 DOI: 10.1111/j.1478-3231.2011.02526.x]
97. Lallukka S, Sevastianova K, Perttilä J, Hakkarainen A, Orho-Melander M, Lundbom N, Olkkonen VM, Yki-Järvinen H. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia 2013; 56: 886-892 [PMID: 23334462 DOI: 10.1007/s00125-013-2829-9]
98. Petit JM, Guiu B, Masson D, Duvillard L, Jooste V, Buffier P, Bouillet B, Brindisi MC, Robin I, Gambert P, Verges B, Cercueil JP, Hillon P. PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes. Liver Int 2011; 31: 1332-1336 [PMID: 21745307 DOI: 10.1111/j.1478-3231.2011.02566.x]
99. Watt KD, Dierkhising R, Fan C, Heimbach JK, Tillman H, Goldstein D, Thompson A, Krishnan A, Charlton MR. Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease. Am J Transplant 2013; 13: 2450-2457 [PMID: 23859071 DOI: 10.1111/ajt.12355]
100. Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 2008; 19: 295-300 [PMID: 18460922 DOI: 10.1097/MOL.0b013e3282ff5e55] (Pubitemid 351653569)
101. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP, Li YX, Diehl AM. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007; 45: 1366-1374 [PMID: 17476695 DOI: 10.1002/hep.21655] (Pubitemid 46918320)
102. Chitraju C, Trötzmüller M, Hartler J, Wolinski H, Thallinger GG, Haemmerle G, Zechner R, Zimmermann R, Köfeler HC, Spener F. The impact of genetic stress by ATGL deficiency on the lipidome of lipid droplets from murine hepatocytes. J Lipid Res 2013; 54: 2185-2194 [PMID: 23740967 DOI: 10.1194/jlr.M037952]
103. Fuchs CD, Claudel T, Kumari P, Haemmerle G, Pollheimer MJ, Stojakovic T, Scharnagl H, Halilbasic E, Gumhold J, Silbert D, Koefeler H, Trauner M. Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice. Hepatology 2012; 56: 270-280 [PMID: 22271167 DOI: 10.1002/hep.25601]
104. Duivenvoorden I, Teusink B, Rensen PC, Romijn JA, Havekes LM, Voshol PJ. Apolipoprotein C3 deficiency results in diet-induced obesity and aggravated insulin resistance in mice. Diabetes 2005; 54: 664-671 [PMID: 15734841] (Pubitemid 40322068)
105. Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, Cobelli C, Shulman GI. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. Proc Natl Acad Sci USA 2006; 103: 18273-18277 [PMID: 17114290 DOI: 10.1073/pnas.0608537103] (Pubitemid 44871648)
106. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, Zhang XM, Dziura J, Lifton RP, Shulman GI. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N Engl J Med 2010; 362: 1082-1089 [PMID: 20335584 DOI: 10.1056/NEJMoa0907295]
107. Hyysalo J, Stojkovic I, Kotronen A, Hakkarainen A, Sevastianova K, Makkonen J, Lundbom N, Rissanen A, Krauss RM, Melander O, Orho-Melander M, Yki-Järvinen H. Genetic variation in PNPLA3 but not APOC3 influences liver fat in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2012; 27: 951-956 [PMID: 22141340 DOI: 10.1111/j.1440-1746.2011.07045.x]
108. Santoro N, Zhang CK, Zhao H, Pakstis AJ, Kim G, Kursawe R, Dykas DJ, Bale AE, Giannini C, Pierpont B, Shaw MM, Groop L, Caprio S. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012; 55: 781-789 [PMID: 22105854 DOI: 10.1002/hep.24806]
109. Li H, Xu R, Peng X, Wang Y, Wang T. Association of glucokinase regulatory protein polymorphism with type 2 diabetes and fasting plasma glucose: a meta-analysis. Mol Biol Rep 2013; 40: 3935-3942 [PMID: 23307301 DOI: 10.1007/s11033-012-2470-6]
110. Fu D, Cong X, Ma Y, Cai H, Cai M, Li D, Lv M, Yuan X, Huang Y, Lv Z. Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects. PLoS One 2013; 8: e55727 [PMID: 23441155 DOI: 10.1371/journal.pone.0055727]
111. Yang Z, Wen J, Tao X, Lu B, Du Y, Wang M, Wang X, Zhang W, Gong W, Ling C, Wu S, Hu R. Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people. Mol Biol Rep 2011; 38: 1145-1150 [PMID: 20625834 DOI: 10.1007/s11033-010-0212-1]
112. Tan HL, Zain SM, Mohamed R, Rampal S, Chin KF, Basu RC, Cheah PL, Mahadeva S, Mohamed Z. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. J Gastroenterol 2014; 49: 1056-1064 [PMID: 23800943 DOI: 10.1007/s00535-013-0850-x]
113. Lee HJ, Su Y, Yin PH, Lee HC, Chi CW. PPAR(gamma)/ PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells. Anticancer Res 2009; 29: 5057-5063 [PMID: 20044617]
114. Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T, Mawatari H, Iida H, Kato S, Hosono K, Fujita K, Yoneda K, Takahashi H, Kirikoshi H, Kobayashi N, Inamori M, Abe Y, Kubota K, Saito S, Maeyama S, Wada K, Nakajima A. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2008; 8: 27 [PMID: 18588668 DOI: 10.1186/1471-230x-8-27]
115. Leone TC, Lehman JJ, Finck BN, Schaeffer PJ, Wende AR, Boudina S, Courtois M, Wozniak DF, Sambandam N, Bernal-Mizrachi C, Chen Z, Holloszy JO, Medeiros DM, Schmidt RE, Saffitz JE, Abel ED, Semenkovich CF, Kelly DP. PGC-1alpha deficiency causes multi-system energy metabolic derangements: muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol 2005; 3: e101 [PMID: 15760270 DOI: 10.1371/journal.pbio.0030101]
116. Hui Y, Yu-Yuan L, Yu-Qiang N, Wei-Hong S, Yan-Lei D, Xiao-Bo L, Yong-Jian Z. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int 2008; 28: 385-392 [PMID: 17999673 DOI: 10.1111/j.1478-3231.2007.01623.x] (Pubitemid 351279587)
117. Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr 2013; 97: 326-331 [PMID: 23269818 DOI: 10.3945/ajcn.112.046417]
118. Lira VA, Benton CR, Yan Z, Bonen A. PGC-1alpha regulation by exercise training and its influences on muscle function and insulin sensitivity. Am J Physiol Endocrinol Metab 2010; 299: E145-E161 [PMID: 20371735 DOI: 10.1152/ajpendo.00755.2009]
119. Gawrieh S, Marion MC, Komorowski R, Wallace J, Charlton M, Kissebah A, Langefeld CD, Olivier M. Genetic variation in the peroxisome proliferator activated receptor-gamma gene is associated with histologically advanced NAFLD. Dig Dis Sci 2012; 57: 952-957 [PMID: 22160635 DOI: 10.1007/s10620-011-1994-2]
120. Cao CY, Li YY, Zhou YJ, Nie YQ, Wan YJ. The C-681G polymorphism of the PPAR-γ gene is associated with susceptibility to non-alcoholic fatty liver disease. Tohoku J Exp Med 2012; 227: 253-262 [PMID: 22820754]
121. Bhatt SP, Nigam P, Misra A, Guleria R, Luthra K, Pandey RM, Pasha MA. Association of peroxisome proliferator activated receptor-γ gene with non-alcoholic fatty liver disease in Asian Indians residing in north India. Gene 2013; 512: 143-147 [PMID: 23031808 DOI: 10.1016/j.gene.2012.09.067]
122. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83: 461S-465S [PMID: 16470013] (Pubitemid 44713219)
123. Hernaez R, McLean J, Lazo M, Brancati FL, Hirschhorn JN, Borecki IB, Harris TB, Nguyen T, Kamel IR, Bonekamp S, Eberhardt MS, Clark JM, Kao WH, Speliotes EK. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol 2013; 11: 1183-1190.e2 [PMID: 23416328 DOI: 10.1016/j.cgh.2013.02.011]
124. Araneta MR, Barrett-Connor E. Adiponectin and ghrelin levels and body size in normoglycemic Filipino, African- American, and white women. Obesity (Silver Spring) 2007; 15: 2454-2462 [PMID: 17925471 DOI: 10.1038/oby.2007.291] (Pubitemid 350034039)
125. Finelli C, Tarantino G. What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol 2013; 19: 802-812 [PMID: 23430039 DOI: 10.3748/wjg.v19.i6.802]
126. Musso G, Gambino R, De Michieli F, Durazzo M, Pagano G, Cassader M. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology 2008; 47: 1167-1177 [PMID: 18311774 DOI: 10.1002/hep.22142] (Pubitemid 351547903)
127. Wong VW, Wong GL, Tsang SW, Hui AY, Chan AW, Choi PC, So WY, Tse AM, Chan FK, Sung JJ, Chan HL. Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people. J Gastroenterol Hepatol 2008; 23: 914-921 [PMID: 18565022 DOI: 10.1111/j.1440-1746.2008.05344.x] (Pubitemid 351806578)
128. Zhang H, Mo X, Hao Y, Gu D. Association between polymorphisms in the adiponectin gene and cardiovascular disease: a meta-analysis. BMC Med Genet 2012; 13: 40 [PMID: 22639977 DOI: 10.1186/1471-2350-13-40]
129. Xi B, He D, Wang Q, Xue J, Liu M, Li J. Common polymorphisms (rs2241766 and rs1501299) in the ADIPOQ gene are not associated with hypertension susceptibility among the Chinese. Mol Biol Rep 2012; 39: 8771-8775 [PMID: 22714914 DOI: 10.1007/s11033-012-1739-0]
130. Han LY, Wu QH, Jiao ML, Hao YH, Liang LB, Gao LJ, Legge DG, Quan H, Zhao MM, Ning N, Kang Z, Sun H. Associations between single-nucleotide polymorphisms (+45T>G, +276G>T, -11377C>G, -11391G>A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetologia 2011; 54: 2303-2314 [PMID: 21638131 DOI: 10.1007/s00125-011-2202-9]
131. Li Y, Yang Y, Shi L, Li X, Zhang Y, Yao Y. The association studies of ADIPOQ with type 2 diabetes mellitus in Chinese populations. Diabetes Metab Res Rev 2012; 28: 551-559 [PMID: 22539443 DOI: 10.1002/dmrr.2309]
132. Zhou W, Liu Y, Zhong DW. Adiponectin (ADIPOQ) rs2241766 G/T polymorphism is associated with risk of cancer: evidence from a meta-analysis. Tumour Biol 2013; 34: 493-504 [PMID: 23143890 DOI: 10.1007/s13277-012-0574-1]
133. Xu Y, He B, Pan Y, Gu L, Nie Z, Chen L, Li R, Gao T, Wang S. The roles of ADIPOQ genetic variations in cancer risk: evidence from published studies. Mol Biol Rep 2013; 40: 1135-1144 [PMID: 23065236 DOI: 10.1007/s11033-012-2154-2]
134. Muhidin SO, Magan AA, Osman KA, Syed S, Ahmed MH. The relationship between nonalcoholic fatty liver disease and colorectal cancer: the future challenges and outcomes of the metabolic syndrome. J Obes 2012; 2012: 637538 [PMID: 23304464 DOI: 10.1155/2012/637538]
135. Lu H, Sun J, Sun L, Shu X, Xu Y, Xie D. Polymorphism of human leptin receptor gene is associated with type 2 diabetic patients complicated with non-alcoholic fatty liver disease in China. J Gastroenterol Hepatol 2009; 24: 228-232 [PMID: 18713300 DOI: 10.1111/j.1440-1746.2008.05544.x]
136. Swellam M, Hamdy N. Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptor. IUBMB Life 2012; 64: 180-186 [PMID: 22215535 DOI: 10.1002/iub.597]
137. Dubern B, Clement K. Leptin and leptin receptor-related monogenic obesity. Biochimie 2012; 94: 2111-2115 [PMID: 22627381 DOI: 10.1016/j.biochi.2012.05.010]
138. Perfield JW, Ortinau LC, Pickering RT, Ruebel ML, Meers GM, Rector RS. Altered Hepatic Lipid Metabolism Contributes to Nonalcoholic Fatty Liver Disease in Leptin-Deficient Ob/Ob Mice. J Obes 2013; 2013: 8 [DOI: 10.1155/2013/296537]
139. Zain SM, Mohamed Z, Mahadeva S, Cheah PL, Rampal S, Chin KF, Mahfudz AS, Basu RC, Tan HL, Mohamed R. Impact of leptin receptor gene variants on risk of non-alcoholic fatty liver disease and its interaction with adiponutrin gene. J Gastroenterol Hepatol 2013; 28: 873-879 [PMID: 23278404 DOI: 10.1111/jgh.12104]
140. Tilg H . The role of cytokines in non-alcoholic fatty liver disease. Dig Dis 2010; 28: 179-185 [PMID: 20460908 DOI: 10.1159/000282083]
141. Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A. Evaluation of inflammatory and angiogenic factors in patients with nonalcoholic fatty liver disease. Cytokine 2012; 59: 442-449 [PMID: 22658783 DOI: 10.1016/j.cyto.2012.05.001]
142. Wang JK, Feng ZW, Li YC, Li QY, Tao XY. Association of tumor necrosis factor-α gene promoter polymorphism at sites -308 and -238 with non-alcoholic fatty liver disease: a meta-analysis. J Gastroenterol Hepatol 2012; 27: 670-676 [PMID: 22097889 DOI: 10.1111/j.1440-1746.2011.06978.x]
143. Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozzi E, Leathart JB, Pietrobattista A, Burt AD, Maggioni M, Fracanzani AL, Lattuada E, Zappa MA, Roviaro G, Marchesini G, Day CP, Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 267-273 [PMID: 20176643 DOI: 10.1136/gut.2009.190801]
144. Aparicio-Vergara M, Hommelberg PP, Schreurs M, Gruben N, Stienstra R, Shiri-Sverdlov R, Kloosterhuis NJ, de Bruin A, van de Sluis B, Koonen DP, Hofker MH. Tumor necrosis factor receptor 1 gain-of-function mutation aggravates non-alcoholic fatty liver disease but does not cause insulin resistance in a murine model. Hepatology 2013; 57: 566-576 [PMID: 22941955 DOI: 10.1002/hep.26046]
145. Giannitrapani L, Soresi M, Balasus D, Licata A, Montalto G. Genetic association of interleukin-6 polymorphism (-174 G/ C) with chronic liver diseases and hepatocellular carcinoma. World J Gastroenterol 2013; 19: 2449-2455 [PMID: 23674845 DOI: 10.3748/wjg.v19.i16.2449]
146. Carulli L, Canedi I, Rondinella S, Lombardini S, Ganazzi D, Fargion S, De Palma M, Lonardo A, Ricchi M, Bertolotti M, Carulli N, Loria P. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig Liver Dis 2009; 41: 823-828 [PMID: 19403348 DOI: 10.1016/j.dld.2009.03.005]